Silo Pharma announced a Notice of Allowance from the Canadian Intellectual Property Office for a patent application covering its lead asset, SPC-15, for PTSD and stress-induced disorders. This expands the company's intellectual property protection for a key therapeutic program into another major market, following a recent European patent grant.
Silo Pharma has secured a Notice of Allowance for a Canadian patent covering SPC-15, an intranasal 5-HT4 receptor agonist targeting PTSD and other stress-induced psychiatric disorders. This is significant as it expands the intellectual property protection for their lead therapeutic program into another major international market, following a recent European patent grant. This strengthens Silo's competitive position and provides a more secure foundation for future development, manufacturing, and commercialization of SPC-15. For traders, this is a moderately positive development, as it de-risks the asset to some extent and could attract further investment or partnership interest in the long term, though the immediate short-term market impact might be limited given the developmental stage of the company.